Introduction: Multimodality therapy has curative potential in locally advanced NSCLC. Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology Radiation Therapy Oncology Group (RTOG) 0229 demonstrated the feasibility and efficacy of combining full-dose radiation (61.2 Gy) with chemotherapy followed by resection and chemotherapy. On the basis of that experience and evidence that EGFR antibodies are radiosensitizing, we explored adding panitumumab to CRT followed by resection and consolidation chemotherapy in locally advanced NSCLC with a primary end point of MNS.
reassessed before or at the time of resection. Consolidation chemotherapy was weekly carboplatin (area under the curve ¼ 6) and paclitaxel, 200 mg/m 2 every 21 days for two courses. The study was designed to detect an improvement in MNS from 52% to 72%. With use of a 0.15 one-sided type 1 error and 80% power, 97 patients were needed.
Results:
The study was opened in November 2010 and closed in August 2015 by the Data Monitoring Committee after 71 patients had been accrued for futility and excessive toxicity in the experimental arm. A total of 60 patients were eligible: 19 patients (86%) who received CRT and 29 (76%) who received CRT plus panitumumab and underwent an operation. With regard to postoperative toxicity, there were three grade 4 adverse events (13.6%) and no grade 5 adverse events (0%) among those who received CRT versus six grade 4 (15.8%) and four grade 5 adverse events (10.5%) among those who received CRT plus panitumumab. The MNS rates were 68.2% (95% confidence interval: 45.1-86.1) and 50.0% (95% confidence interval: 33.4-66.6) for CRT and CRT plus panitumumab, respectively (p ¼ 0.95).
Conclusion:
The addition of panitumumab to CRT did not improve MNS. There was an unexpectedly high mortality rate in the panitumumab arm, although the relationship to panitumumab is unclear. The control arm had outcomes similar to those in NRG Oncology RTOG 0229.
Introduction
Concurrent chemoradiotherapy (CRT) without surgery is currently accepted as the standard of care for the treatment of patients with locally advanced NSCLC. 1 However, there remains a substantial rate (>30%) of local relapse as the first site of failure. 2 Therefore, the possibility of improving outcome by utilizing trimodality therapy (i.e., chemotherapy, radiotherapy, and surgery) is attractive. Pulmonary resection after induction therapy with chemotherapy and radiotherapy to 45 Gy has now been well documented to be feasible and safe. Two large prospective cooperative group studies, SWOG 8805 and the Pancoast Intergroup study (INT 0160) , demonstrated the ability to perform either lobectomy or pneumonectomy after neoadjuvant concurrent chemotherapy and radiotherapy in a multiinstitutional setting. 3, 4 Induction radiotherapy in these trials was limited to 45 Gy, primarily out of concern regarding the excess morbidity and mortality that has been attributed to surgical resection after high-dose radiotherapy.
NRG Oncology Radiation Therapy Oncology Group (RTOG) 9309 tested the need for surgery as part of the treatment plan for locally advanced (N2) NSCLC. 5 The primary end point for the study (improved overall survival) was not met. However, there was a significant improvement in progression-free survival. The discrepancy was due to unacceptably high mortality in patients undergoing pneumonectomy. This may be an artifact of lack of surgical expertise with the postoperative management of these patients. NRG Oncology RTOG 0229 required certification of surgical expertise and enrolled 60 patients with pathologically documented N2 to N3 NSCLC from 19 RTOG institutions. The treatment strategy used "full-dose" radiotherapy (i.e., 60 Gy) concurrently with low-dose carboplatin/paclitaxel followed by resection and then full-dose carboplatin/ paclitaxel. Of the 43 patients who were evaluable for the primary end point of mediastinal sterilization, seven had residual mediastinal disease and were not offered resection, 34 had a lobectomy, and three had a pneumonectomy. Mediastinal clearance was achieved in 27 patients (63%). There was a 14% (five of 37) incidence of grade 3 postoperative pulmonary complications and only one postoperative grade 5 adverse event (AE) (3%). The primary sites of failure were the brain (19%), ipsilateral lung (18%), and regional nodes (16%). 6 In summary, this trial implied that with appropriate surgical expertise, an aggressive multimodality treatment of locally advanced lung cancer can be accomplished in the cooperative group setting with low levels of surgical morbidity and mortality.
Antibodies to the EGFR have been demonstrated to potentiate the effects of radiation. A phase III trial in head and neck cancer demonstrated superiority of cetuximab combined with radiotherapy versus radiotherapy alone. 7 NRG Oncology RTOG 0324 (N ¼ 93) combined carboplatin, paclitaxel, radiotherapy, and cetuximab in treatment of patients with inoperable stage III disease. There was no selection based on EGFR status.
The preliminary survival data demonstrate a 24-month median overall survival, which is among the best ever demonstrated for a cooperative group study population. Importantly, other than rash, there was little evidence that the use of cetuximab was associated with increased toxicity. 8 Another cooperative group study, CALGB 30407, evaluated carboplatin, pemetrexed, cetuximab, and concurrent radiotherapy versus carboplatin, pemetrexed, and concurrent radiotherapy. Other than increased rash, there was no difference in toxicity. 9 Specifically, in neither trial was the use of the EGFR antibody associated with increased pulmonary toxicity. Panitumumab is a high-affinity fully human immunoglobulin G2 monoclonal antibody against EGFR. Compared with cetuximab, it is much less likely to cause severe infusion reactions and does not require premedication or a loading dose.
Emerging from recent studies of aggressive bimodality and trimodality treatment of locally advanced NSCLC is the importance of mediastinal clearance. Mediastinal sterilization after CRT is strongly associated with overall survival and can serve as a surrogate marker for long-term benefit. In SWOG 8805, 107 patients who underwent concurrent CRT followed by surgical resection were evaluated. The median survival time and 3-year survival rate were 30 months and 44% for the 48 patients (45% of the surgical population and 38% of the intent-to-treat population) who were mediastinal node-negative versus 10 months and 18% for all others (p ¼ 0.0005). 10 NRG Oncology RTOG 0839 was designed to test the hypothesis that the addition of an EGFR antibody to standard CRT could potentially improve outcome in locally advanced NSCLC treated with trimodality therapy (concurrent CRT followed by surgical resection). As in NRG Oncology RTOG 0229, an end point of mediastinal sterilization would be used to determine efficacy and surgical expertise would need to be demonstrated for an institution to participate.
Materials and Methods

Patients and Treatment Plan
Patients with histologically documented NSCLC, stage IIIa (N2 positive, sixth edition) disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and normal organ function (serum creatinine level <1.5 and normal liver function test results) were potentially eligible. Mediastinal involvement needed to be demonstrated pathologically, and mediastinal nodes needed to be smaller than 3 cm. Before enrollment, the patient needed to be deemed potentially resectable and suitable for trimodality therapy by a multimodality team that included a medical oncologist, radiation oncologist, and thoracic surgeon. Surgeons were required to be board-certified in thoracic surgery and must have demonstrated expertise in performing resections after concurrent CRT. Specifically, they were required to have performed at least 10 lobectomies/pneumonectomies in the past year (a minimum of five after CRT). Furthermore, they needed to state that they would adhere to specific management guidelines regarding the resection, mediastinal assessment, and postoperative care. Credentials of the participating surgeons were reviewed by the surgical cochair (J.D.) before the surgeon's institution was allowed to particpate. Concurrent CRT consisted of weekly carboplatin (AUC ¼2.0), paclitaxel (50 mg/m 2 ), and radiation of 60 Gy delivered in 30 fractions (2 Gy per fraction). Patients in the experimental arm also received panitumumab at 2.5 mg/kg weekly for 6 weeks during CRT. The mediastinum was pathologically reassessed before or at the time of resection. Consolidation chemotherapy consisted of carboplatin (area under the curve ¼ 6) and paclitaxel, 200 mg/m 2 every 21 days, for two courses. All sites were required to have obtained local institutional review board approval before patient enrollment, and all patients were required to provide written informed consent. The study was registered with ClinicalTrials.gov (NCT00979212).
The study used a randomized phase II design (Fig. 1) . One arm utilized the regimen used in NRG Oncology RTOG 0229. The second arm used the same regimen with the addition of panitumumab. The control arm (the NRG Oncology RTOG 0229 arm) served several purposes: (1) it allowed for direct comparison of toxicities (both acute and late) that might result from the addition of panitumumab; (2) it anchored the present trial, as this arm is directly comparable to the NRG Oncology RTOG 0229, and ensured that the population treated in NRG Oncology RTOG 0839 was similar; and (3) it would provide adequate samples to allow for the correlative studies. A 2:1 randomization between the panitumumab containing arm and the control arm (NRG Oncology RTOG 0229 arm) allowed for the evaluations described while minimizing the required numbers of patients.
Statistical Considerations
The primary end point of this study was the proportion of patients with a mediastinal nodal clearance after completion of induction chemoradiation with or without panitumumab among all eligible patients. Assessment of mediastinal clearance would occur either before or at the time of planned definitive surgery. The rate of a mediastinal clearance was calculated as the number of patients who have a mediastinal clearance by the total number of analyzable patients at 4 weeks after completion of induction chemoradiation with or without panitumumab and within 2 weeks before anticipated surgery in each arm. Patients who did not undergo mediastinal assessment were considered as not having mediastinal clearance. Analyzable patients were defined as eligible patients who received any protocol treatment. We hypothesized that at least 72% of patients would have a mediastinal clearance with the experimental treatment (arm 2), improving the rate by 20% over that of the control arm (OR ¼ 2.37). The sample size was calculated for OR of proportions (H0: OR 1 versus HA: OR > 1), with a one-sided significance level of 0.15 (the probability of a false-positive result) and 80% statistical power (the probability of a false-negative result being 0.2). One interim analysis of efficacy and futility based on group sequential testing was planned when 50% of analyzable cases were available. 11, 12 A total of 92 patients were required, 61 for arm 2 and 31 for arm 1, which would provide an actual statistical power of 78.7%. With adjustment of the number of cases for ineligible patients or those not starting the protocol treatment by 5% for each arm, a maximum enrollment of 97 patients was anticipated (64 for arm 2 and 33 for arm 1). Tumor response and disease progression were evaluated by using the Response Evaluation Criteria in Solid Tumors, version 1.1. 13 AEs were evaluated by using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Fisher's exact test was used to formally determine whether the mediastinal clearance rates were the same, and the associated 95% confidence interval was calculated by using the Clopper-Pearson method.
14 All outcome times were calculated from the date of randomization to the date of failure or, if no failure, the date of last follow-up. The Kaplan-Meier method was used to estimate the overall survival rates and progression-free survival rates. 15 The rates of distant failure were estimated with the cumulative incidence method by taking into account competing risks. 16 
Results
The study was opened in November 2010 and closed in August 2015 by the Data Monitoring Committee after review of the planned interim analyses for efficacy and futility as well safety analysis. A total of 71 patients were accrued. This report includes all data received through November 9, 2016. Sixty patients were deemed eligible (Fig. 2) . Demographic characteristics are listed in Table 1 . Nineteen patients (86%) undergoing CRT and 29 patients (76%) in the panitumumab arm underwent an operation. Toxicity was considered for the three stages of therapy: induction CRT, surgery, and consolidation chemotherapy (Tables 2-4 ). There were no unexpected toxicities during induction CRT. Toxicity rates for esophageal symptoms were similar between the two arms. There was an increased incidence of rash in the panitumumab arm, which is consistent with the known toxicity of that agent. In the postoperative period there were differences between the two arms. Of AEs reported at any time, three (13.6%) grade 4 AEs and no (0%) grade 5 AEs were seen ion the CRT-alone arm as opposed to six (15.8%) grade 4 AEs and four (10.5%) grade 5 AEs seen in the panitumumab arm. These events occurred before the administration of consolidation chemotherapy.
There was no distinct pattern to the four fatal events in the experimental arm. They occurred at different institutions. The first event was a pulmonary embolus/ deep venous thrombosis and possible radiation pneumonitis in a 71-year-old female that occurred on day 43 after a right middle lobe resection. The second was respiratory failure that began 8 days postoperatively in a 61-year-old female after left pneumonectomy. Medical care was withdrawn by the family despite patient improvement. The third patient was a 52-year-old male in whom a necrotic latissimus flap and sepsis developed 8 days postoperatively. The final event occurred in a 61-year-old male in whom a bronchopleural fistula and sepsis developed 8 days after a right upper lobectomy.
The mediastinal nodal sterilization rates were 68.2% (95% confidence interval: 45.1-86.1) and 50.0% (95% confidence interval: 33.4-66.6%), for CRT and CRT plus P, respectively (p ¼ 0.95) ( Table 5 ). Progression-free and overall survival were similar between the two arms (Fig. 3) . On the basis of the totality of the efficacy and safety data, the study team and the independent data and safety and monitoring board determined that it was inappropriate to continue the trial.
Discussion
Combined therapy targeted to improve local and systemic control in nonoperative studies has demonstrated that improvements in local control may lead to improved overall survival. The addition of concurrent radiotherapy to systemic therapy has been shown to improve survival versus chemotherapy alone or sequentially delivered chemotherapy and radiotherapy. 17, 18 The persistence of localized disease after CRT justifies the evaluation of surgical resection in this setting. As noted, NRG Oncology RTOG 9309 provided a strong signal that surgery could improve outcome if the early mortality associated with surgery could be limited. There is considerable evidence that high-volume institutions with experienced teams can optimize the outcome for both operative and nonoperative treatment in NSCLC. [19] [20] [21] Therefore, we required that all participating surgeons be board-certified in thoracic surgery and demonstrate expertise in resection after concurrent CRT. In addition, the protocol provided guidance regarding the surgical techniques to be used, as well as intraoperative and postoperative care. NRG Oncology RTOG 0229 demonstrated the feasibility of such an approach. In 37 patients who underwent resection after concurrent CRT, there was only a single postoperative death. Mediastinal nodal sterilization was achieved in more than 50% of the patients. In the current study, we attempted to extend the results of NRG Oncology RTOG 0229 and evaluate the utility of anti-EGFR therapy to enhance radiotherapy. However, we encountered severe and unexpected toxicity in the experimental arm, which led to early cessation of the trial. The relationship of this toxicity to the experimental agent is unclear.
At the time the study was formulated, the results of NRG Oncology RTOG 0617, which was evaluating the addition of the EGFR antibody cetuximab to CRT (both as part of induction as well as consolidation) in the nonoperative setting, were unknown. 22 In that trial, cetuximab was used both as part of CRT and during Includes acute coronary syndrome, cardiac arrest, atrial fibrillation/flutter, myocardial infarction, sinus tachycardia, and ventricular arrythmia. CRT, chemoradiotherapy; CRT þ P, chemoradiotherapy plus panitumumab.
consolidation. No advantage was demonstrated by the addition of cetuximab. CALGB 30407 asked a question similar to that asked in RTOG 0617. The question asked in NRG Oncology RTOG 0839 was fundamentally different in that the addition of an EGFR antibody to chemotherapy was to evaluate its role solely as a radiosensitizer to enhance local control with the end point of mediastinal sterilization. Even though the trial was terminated prematurely, it is unlikely that this hypothesis is correct, given the similarities in mediastinal nodal sterilization between the two arms. Furthermore, the negative results of CRT in combination with an EGFR inhibitor in several different trials (RTOG 0617, CALGB 30407, and RTOG 0839) indicate that this avenue of investigation should be closed, barring some new insights regarding the biology and radiosensitization properties of these drugs. The optimal dose of radiation as part of trimodality therapy for locally advanced NSCLC remains to be established. For definitive CRT, 60 to 66 Gy appears to be optimal. Escalation of radiation dose to 74 Gy in RTOG 0617 resulted in increased mortality, most likely on account of cardiotoxicity. 22 The prior study RTOG 0229 and the control arm of the current study used 60 Gy. The combination of this dose with chemotherapy was based on the premise that it represented a "definitive" regimen and if patients were not able to proceed with surgery, they would still have received an optimal nonoperative regimen. The use of 60 Gy in this setting was extensively evaluated in prior single-institution studies and RTOG 0229. 23, 24 The control arm of the current study performed similarly to RTOG 0229. However, the value of 60 Gy versus 45 Gy has not been established in a phase III trial and should not be considered a standard of care. It is possible that the increased toxicity seen in the experimental arm could be attributed to an interaction of the radiation dose and the EGFR inhibitor. Additional CRT, chemoradiotherapy; CRT þ P, chemoradiotherapy plus panitumumab. Figure 3 . Progression-free survival and overall survival. CI, confidence interval; CRT, chemoradiotherapy; CRT þ P, chemoradiotherapy plus panitumumab.
analysis of the surgical outcomes of this trial and RTOG 0229 will be reported in a subsequent manuscript.
In conclusion, NRG Oncology RTOG 0839 failed to demonstrate an advantage for the addition of an EGFR antibody as a method of enhancing CRT for locally advanced NSCLC.
